PROM1 and glioblastoma: These findings suggest that the CD133+ glioblastoma cell subpopulation has a stronger malignant cell phenotype than the CD133− subpopulation and that its recurrence rate is increased compared with the primitive tumorigenic rate following in vivo transplantation.